IMMUNIC INC
IMMUNIC INC logo
IMUX

IMMUNIC INC (IMUX)

$2.8711.67%

Market is closed
– opens on 8 PM, 06 Feb 2023
  • $

1D

1W

1M

1Y

3Y

5Y

Key Stats

$2.5306
Day's Range
$2.8984
$1.11
52-Week Range
$14.5
1 month return112.59%
3 month return100.7%
1 year return78.31%
5 year return50.52%

Analyst Recommendation

based on 12 analysts ratings

Buy
83%
Buy
16%
Hold
0%
Sell

Based on 12 Wall street analysts offering stock ratings for IMMUNIC INC(by analysts ranked 0 to 5 stars)

Analyst Forecast

What analysts predicted

Upside of 625.78%

Current

$2.87

Target

$20.83

Recommendation Trend

Based on 12 analyst

Current1M Ago3M Ago
Buy
10
10
11
Hold
2
2
1
Sell
0
0
0
Consensus
BUY
BUY
BUY

Company Financials

  • Annual
  • Quarterly

Highlights

Market Capitalization114.0M
Book Value$3.56
Dividend Share0.0
Dividend Yield0.0%
Earnings Per Share (EPS)-3.12
Wall Street Target Price20.83

Valuation

Trailing PE0.0
Forward PE0.0
Price/Book (mrq)0.43
Enterprise Value-25288375
Enterprise Value/Revenue0.0
Enterprise Value/Ebitda0.3

Technicals

Beta1.44
50 Day MA1.5
200 Day MA3.76

Institutional Holdings

RTW INVESTMENTS, LLC

6.23%

Omega Fund Management LLC

4.03%

Gratus Capital LLC

3.76%

Point72 Asset Management, L.P.

2.99%

Millennium Management LLC

2.72%

COWEN AND COMPANY, LLC

2.71%

Company Information

Immunic, Inc. is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including relapsing-remitting multiple sclerosis, ulcerative colitis, Crohn's disease, and psoriasis. Immunic is developing three small molecule products: its lead development program, IMU-838, is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH and exhibits a host-based antiviral effect; IMU-935 is an inverse agonist of RORγt; and IMU-856 targets the restoration of the intestinal barrier function. Immunic announced positive results from its phase 2 EMPhASIS trial of IMU-838 in patients with relapsing-remitting multiple sclerosis, reporting achievement of both primary and key secondary endpoints with high statistical significance. IMU-838 is also in phase 2 clinical development for ulcerative colitis and COVID-19, with an additional phase 2 trial considered in Crohn's disease. An investigator-sponsored proof-of-concept clinical trial for IMU-838 in primary sclerosing cholangitis is ongoing at the Mayo Clinic.
OrganizationIMMUNIC INC
Employees65
CEODr. Duane D. Nash M.B.A., M.D., J.D., M.B.A
IndustryPharmaceuticals: Major

Discover more

Frequently Asked Questions

What is IMMUNIC INC share price today?

Can Indians buy IMMUNIC INC shares?

How can I buy IMMUNIC INC shares from India?

Can Fractional shares of IMMUNIC INC be purchased?

What are the documents required to start investing in IMMUNIC INC stocks?

What are today’s High and Low prices of IMMUNIC INC?

What are today’s traded volumes of IMMUNIC INC?

What is today’s market capitalisation of IMMUNIC INC?

What is the 52 Week High and Low Range of IMMUNIC INC?

How much percentage IMMUNIC INC is down from its 52 Week High?

How much percentage IMMUNIC INC is up from its 52 Week low?

What are the historical returns of IMMUNIC INC?

Who is the Chief Executive Officer (CEO) of IMMUNIC INC?

Trading and brokerage services provided by

Banking and Remittance services provided by

Technology services provided by : Finzoomers Services Private Limited

Disclaimer: These services are not for exchange traded products.The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Finzoomers Services Private Limited acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*